Table 3.
Mean individual change of three anthropometric measures, from start to end of treatment (exit or 6 months), comparing 20 mg group to the placebo group (reference).
| All (N = 401) | Premenopausal (n = 149) | Postmenopausal (n = 252) | Interaction menopausal status | ||||
|---|---|---|---|---|---|---|---|
| Anthropometrics | Mean change 20 to 0 mg (ref.)a |
95% confidence interval |
Mean change 20 to 0 mg (ref.)a |
95% confidence interval | Mean change 20 to 0 mg (ref.)a |
95% confidence interval | P valueb |
| BMI (kg/m2) | −0.22 | [−0.37, −0.06] | −0.28 | [−0.56, −0.01] | −0.17 | [−0.35, 0.02] | 0.505 |
| Weight (kg) | −0.59 | [−1.01, −0.16] | −0.80 | [−1.55, −0.05] | −0.43 | [−0.92, 0.07] | 0.417 |
| Waist circumference (cm) | −0.74 | [−2.57, 1.08] | −3.53 | [−6.73, −0.32] | 0.94 | [−1.24, 3.12] | 0.024 |
BMI body mass index.
aDifference in mean change comparing 20 to 0 mg (ref.) tamoxifen at end of treatment (at 6 months or date of discontinuation).
bP values for interaction of menopausal status on the effect of tamoxifen.
Significant values are in bold (P < 0.05).